Literature DB >> 31400013

Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation.

Iman Abou Dalle1, Hagop Kantarjian1, Sarah A Bannon2, Rashmi Kanagal-Shamanna3, Mark Routbort3, Keyur P Patel3, Shimin Hu3, Kapil Bhalla1, Guillermo Garcia-Manero1, Courtney D DiNardo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31400013     DOI： 10.1002/ajh.25610

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  12 in total

Review 1.  The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition.

Authors:  Rashmi Kanagal-Shamanna
Journal:  Curr Hematol Malig Rep       Date:  2021-05-24       Impact factor: 3.952

Review 2.  Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms.

Authors:  Talha Badar; Timothy Chlon
Journal:  Curr Hematol Malig Rep       Date:  2022-07-04       Impact factor: 4.213

3.  DDX41 is required for cGAS-STING activation against DNA virus infection.

Authors:  Ravi Shankar Singh; Venkatasubramanian Vidhyasagar; Shizhuo Yang; Ananna Bhadra Arna; Manisha Yadav; Aanchal Aggarwal; Alexya N Aguilera; Satoru Shinriki; Kalpana Kalyanasundaram Bhanumathy; Kannupriya Pandey; Aizhang Xu; Noreen Rapin; Mark Bosch; John DeCoteau; Jim Xiang; Franco J Vizeacoumar; Yan Zhou; Vikram Misra; Hirotaka Matsui; Susan R Ross; Yuliang Wu
Journal:  Cell Rep       Date:  2022-05-24       Impact factor: 9.995

4.  Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations.

Authors:  Shiqiang Qu; Bing Li; Tiejun Qin; Zefeng Xu; Lijuan Pan; Naibo Hu; Gang Huang; Robert Peter Gale; Zhijian Xiao
Journal:  Br J Haematol       Date:  2020-04-19       Impact factor: 8.615

5.  Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations.

Authors:  Sarah A Bannon; Mark J Routbort; Guillermo Montalban-Bravo; Rohtesh S Mehta; Fatima Zahra Jelloul; Koichi Takahashi; Naval Daver; Betul Oran; Naveen Pemmaraju; Gautam Borthakur; Kiran Naqvi; Ghayas Issa; Koji Sasaki; Yesid Alvarado; Tapan M Kadia; Marina Konopleva; Rashmi Kanagal Shamanna; Joseph D Khoury; Farhad Ravandi; Richard Champlin; Hagop M Kantarjian; Kapil Bhalla; Guillermo Garcia-Manero; Keyur P Patel; Courtney D DiNardo
Journal:  Front Oncol       Date:  2021-01-28       Impact factor: 5.738

6.  Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms.

Authors:  Hassan B Alkhateeb; Ahmad Nanaa; David Viswanatha; James M Foran; Talha Badar; Lisa Sproat; Rong He; Phuong Nguyen; Dragan Jevremovic; Mohamad E Salama; Patricia Greipp; Naseema Gangat; Ayalew Tefferi; Mark R Litzow; Abhishek A Mangaonkar; Mithun Vinod Shah; Mrinal Patnaik; Aref Al-Kali
Journal:  Blood Adv       Date:  2022-01-25

7.  A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report.

Authors:  Woo Yong Shin; Seug Yun Yoon; Rojin Park; Jung-Ah Kim; Ho Hyun Song; Hae In Bang; Jong-Ho Won; Jieun Kim
Journal:  BMC Med Genomics       Date:  2022-03-04       Impact factor: 3.063

Review 8.  Cytogenetic and Genetic Abnormalities with Diagnostic Value in Myelodysplastic Syndromes (MDS): Focus on the Pre-Messenger RNA Splicing Process.

Authors:  Nathalie Douet-Guilbert; Benoît Soubise; Delphine G Bernard; Marie-Bérengère Troadec
Journal:  Diagnostics (Basel)       Date:  2022-07-07

9.  [Lenalidomide for myelodysplastic syndrome with excess blasts with germline DDX41 mutation: a case report and literatures review].

Authors:  J Chen; S Q Qu; T J Qin; Z J Xiao; Z F Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-10-14

Review 10.  Clinical features of DDX41 mutation-related diseases: a systematic review with individual patient data.

Authors:  Ziqi Wan; Bing Han
Journal:  Ther Adv Hematol       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.